ANI Pharmaceuticals, Inc. (ANIP) has 20 known insider and institutional holders on record. The largest holder is MERIDIAN VENTURE PARTNERS II LP with 1,819,259 shares. Other notable holders include SIMES STEPHEN M and Lalwani Nikhil.
Over the last 12 months, insiders have made 103 transactions in ANIP stock — 15 buys (valued at $14.28M) and 47 sells (valued at $37.14M). Insider selling has exceeded buying during this period.
ANIP Insider Ownership
Top Holder
MERIDIAN VENTURE PARTNERS II LP
1,819,259 shares
Buys (12 mo)
15
$14.28M value
Sells (12 mo)
47
$37.14M value
12-Month Transaction Activity
Top Insider Holders
| # |
Name |
Role |
Shares Owned |
Last Filed |
Relative Size |
| 1 |
Meridian Venture Partners Ii Lp |
10 Percent Owner |
1,819,259 |
2023-08-16 |
|
| 2 |
Simes Stephen M |
Vice Chairman, President & CEO |
800,000 |
2012-01-27 |
|
| 3 |
Lalwani Nikhil |
President & CEO |
404,889 |
2026-03-10 |
|
| 4 |
Marshbanks Tracy |
Director |
382,664 |
2018-05-16 |
|
| 5 |
Raynor Daniel |
Director |
294,316 |
2018-03-19 |
|
| 6 |
Donenberg Philip B |
Sr VP of Finance, CFO, Secy |
285,000 |
2012-01-27 |
|
| 7 |
Przybyl Arthur |
President and CEO |
192,424 |
2020-04-08 |
|
| 8 |
Carey Stephen P. |
SVP & CFO |
180,393 |
2026-03-10 |
|
| 9 |
Snabes Michael C |
Sr. VP of Medical Affairs |
165,000 |
2012-01-27 |
|
| 10 |
Marken James G. |
SVP Ops & Prod Dev |
116,006 |
2024-04-11 |
|
| 11 |
Shanmugam Muthusamy |
Head of R&d, COO-novitium Ops |
101,056 |
2026-03-02 |
|
| 12 |
Mutz Christopher |
Head of Rare Disease |
91,309 |
2026-03-13 |
|
| 13 |
Schrepfer Robert W |
SVP - New Bus Dev & Spec Sales |
87,477 |
2021-03-29 |
|
| 14 |
Gutwerg Ori |
SVP, Generics |
81,468 |
2026-03-10 |
|
| 15 |
Cook Meredith |
Sr. VP, General Counsel & Sec. |
79,390 |
2026-03-13 |
|
| 16 |
Gassert Chad |
SVP - Corp. Dev. & Strategy |
77,137 |
2026-03-02 |
|
| 17 |
Davis Krista |
SVP, Chief HR Officer |
57,033 |
2026-03-10 |
|
| 18 |
Walsh Patrick D |
Director |
52,405 |
2026-03-03 |
|
| 19 |
Brown Robert E. Jr |
Director |
49,021 |
2022-04-29 |
|
| 20 |
Rowland Thomas Andrew |
SVP, Head - Established Brands |
38,730 |
2026-03-13 |
|
Recent Transactions (last 12 months)
| Date |
Name |
Role |
Type |
Shares |
Price |
Value |
| 2026-03-13 |
Cook Meredith |
Sr. VP, General Counsel & Sec. |
Informative Sell |
500 |
$72.62 |
$36.31K |
| 2026-03-13 |
Mutz Christopher |
Head of Rare Disease |
Informative Sell |
3,162 |
$71.64 |
$226.53K |
| 2026-03-11 |
Rowland Thomas Andrew |
SVP, Head - Established Brands |
Informative Sell |
4,772 |
$74.91 |
$357.47K |
| 2026-03-09 |
Davis Krista |
SVP, Chief HR Officer |
Informative Sell |
5,087 |
$74.13 |
$377.1K |
| 2026-03-06 |
Davis Krista |
SVP, Chief HR Officer |
Informative Sell |
1,485 |
$75.00 |
$111.38K |
| 2026-03-09 |
Mutz Christopher |
Head of Rare Disease |
Informative Sell |
3,602 |
$74.18 |
$267.2K |
| 2026-03-07 |
Mutz Christopher |
Head of Rare Disease |
Tax Withholding of RSU |
3,314 |
$74.04 |
$245.37K |
| 2026-03-06 |
Mutz Christopher |
Head of Rare Disease |
Informative Sell |
2,121 |
$74.22 |
$157.42K |
| 2026-03-07 |
Gutwerg Ori |
SVP, Generics |
Tax Withholding of RSU |
3,314 |
$74.04 |
$245.37K |
| 2026-03-07 |
Lalwani Nikhil |
President & CEO |
Tax Withholding of RSU |
17,060 |
$74.04 |
$1.26M |
| 2026-03-07 |
Carey Stephen P. |
SVP & CFO |
Tax Withholding of RSU |
5,150 |
$74.04 |
$381.31K |
| 2026-03-05 |
Carey Stephen P. |
SVP & CFO |
Option Exercise (Sell) |
3,312 |
$49.51 |
$163.98K |
| 2026-03-02 |
Mutz Christopher |
Head of Rare Disease |
Informative Sell |
417 |
$74.00 |
$30.86K |
| 2026-03-03 |
Gutwerg Ori |
SVP, Generics |
Informative Sell |
2,060 |
$76.50 |
$157.59K |
| 2026-03-03 |
Walsh Patrick D |
Director |
Informative Sell |
6,000 |
$74.23 |
$445.38K |
| 2026-02-28 |
Davis Krista |
SVP, Chief HR Officer |
Tax Withholding of RSU |
1,555 |
$73.90 |
$114.91K |
| 2026-02-26 |
Davis Krista |
SVP, Chief HR Officer |
RSU Award |
10,810 |
$77.15 |
$833.99K |
| 2026-02-28 |
Cook Meredith |
Sr. VP, General Counsel & Sec. |
Tax Withholding of RSU |
1,555 |
$73.90 |
$114.91K |
| 2026-02-26 |
Cook Meredith |
Sr. VP, General Counsel & Sec. |
RSU Award |
13,895 |
$77.15 |
$1.07M |
| 2026-02-28 |
Gassert Chad |
SVP - Corp. Dev. & Strategy |
Tax Withholding of RSU |
2,221 |
$73.90 |
$164.13K |
| 2026-02-26 |
Gassert Chad |
SVP - Corp. Dev. & Strategy |
RSU Award |
11,116 |
$77.15 |
$857.6K |
| 2026-02-26 |
Shanmugam Muthusamy |
Head of R&d, COO-novitium Ops |
RSU Award |
11,116 |
$77.15 |
$857.6K |
| 2026-02-28 |
Mutz Christopher |
Head of Rare Disease |
Tax Withholding of RSU |
2,221 |
$73.90 |
$164.13K |
| 2026-02-26 |
Mutz Christopher |
Head of Rare Disease |
RSU Award |
21,306 |
$77.15 |
$1.64M |
| 2026-02-28 |
Gutwerg Ori |
SVP, Generics |
Tax Withholding of RSU |
2,221 |
$73.90 |
$164.13K |
